Zeto, Inc. Enhances EEG Technologies with $31 Million Series B Funding

Zeto Inc. Advances EEG Monitoring with $31 Million Funding

Zeto, Inc., an innovative force in medical technology, has successfully secured $31 million in a Series B funding round. This investment will help the company redefine the landscape of EEG (Electroencephalogram) diagnostics, integrating cutting-edge devices with advanced AI functionalities for brain monitoring.

Based in Santa Clara, California, Zeto is reshaping how we approach brain health assessment, making EEG technology accessible in various clinical segments including hospitals, emergency departments, and even at-home care. Their unique product offerings, which include wearable EEG devices, are designed to facilitate continuous monitoring and immediate analysis, ensuring timely responses to neurological events.

The funding round was spearheaded by MindWorks Global (MWG), a Michigan-based investment firm known for its strategic investments in high-growth companies. MWG's founder and CEO, Mike Williams, highlighted Zeto's potential, emphasizing the transformative nature of its technology. “Zeto's vision and technology are truly transformative for the medical arena and beyond,” Williams stated. He expressed confidence that Zeto’s innovations will lead to groundbreaking advancements in brain health assessment.

With years of experience in scaling multiple industries, Mike Williams and his team at MWG bring invaluable expertise and a robust network to Zeto’s board of directors. This collaboration aims not just at capital infusion but at driving significant societal impacts through high-performance company growth.

Aswin Gunasekar, founder and CEO of Zeto, articulated his excitement regarding this pivotal moment for the company. He mentioned the heightened reputation Zeto has garnered within the field, boosted by rapid adoption among leading healthcare institutions across the U.S. The recent funding will allow Zeto to expand its operational capabilities and further its research and development initiatives.

Zeto has successfully developed a cloud-based platform to deliver nationwide monitoring and interpretative services overseen by neurologists, further enhancing the functionality of their wearable devices. The integration of AI into their services offers groundbreaking capabilities for condition alerts related to seizures and epilepsy.

Looking ahead, Zeto is not just stopping at epilepsy management; the company plans to broaden its scope to target conditions such as depression, stroke, and traumatic brain injuries. This strategic expansion marks a significant development in the healthcare sector, aligning with modern standards of remote patient monitoring and virtual healthcare.

Zeto's EEG monitoring systems have received FDA clearance in both 2018 and 2024, marking their commercial viability within the U.S. market. As brain health becomes a focal point in overall wellness, Zeto is poised to make substantial contributions toward integrating advanced diagnostics into everyday healthcare practices.

In the words of Gunasekar, “We are thrilled to welcome MindWorks Global partners who not only provide financial support but also come with significant expertise, experience, and a powerful network.” This partnership will play a crucial role as Zeto embarks on an exciting new chapter that promises to enhance its market presence and technological advancements in EEG monitoring.

Zeto remains grateful for its previous investors and their unwavering support throughout its journey. With this new funding round, the company is set to reinforce its position at the forefront of EEG technology, ensuring it continues to innovate and lead in this critical area of healthcare. For those interested in exploring more about Zeto's offerings, detailed information can be found on their official website Zeto, Inc..

As the demand for modernized healthcare technology continues to grow, Zeto, Inc. exemplifies how innovative solutions can make a real difference in patient care and monitoring.